Thanks for this update, this is great information and very helpful. Although I do wish the funding wasn’t so dilutive, I’m happy about this move now - particularly that Aquitas staff is taking over executive responsibilities. Nothing against Mr. Adams in the least - he seems to have done an admirable job to date and I’ve enjoyed speaking with him in the past - but the job of the investment fund is to make money. I anticipate they’ll push for BTD after the 2a and then, assuming positive results, look to sell or partner while the biotech market is strong. That wouldn’t hurt my feelings.
News 
Market Data 
Discover 
